Published Time：

To further enhance the diagnostic and treatment capabilities of dermatologists in Shenzhen and contribute to the construction of a healthy ecosystem in the fields of remote internet medical care based on skin imaging and targeted therapy for skin diseases, the First Bay Area Skin Health Forum and the 2022 Annual Meeting of the Dermatology Professional Committee of the Shenzhen Health Management Association, hosted by the Dermatology Professional Committee of the Shenzhen Health Management Association and co-organized by Tai Tai Pharmaceutical, a leading enterprise in the field of oral beauty in China, and "Health 160," was successfully held in Shenzhen on November 26th.

Based on clinical needs   Focusing on in-depth topics of skin health

The "Shenzhen Action Plan for Cultivating and Developing the Greater Health Industry Cluster (2022-2025)" proposes to "strive to create a greater health manufacturing industry ecosystem with a reasonable industrial structure and a complete industrial chain, and build a health service demonstration center radiating the Guangdong-Hong Kong-Macao Greater Bay Area," and "strive to become a national gathering highland for the development of the greater health industry."

Under the guidance of this significant policy, Tai Tai Pharmaceutical, a professional brand focusing on the internal regulation and beauty of Chinese women for 30 years, actively responded to the call of the Healthy China 2030 strategic goal, assisted in hosting the First Bay Area Skin Health Forum and the 2022 Annual Meeting of the Dermatology Professional Committee of the Shenzhen Health Management Association, focusing on important topics in dermatology, discussing feasible solutions for the diagnosis and treatment of chloasma, and building a good academic exchange platform for the vigorous development of clinical dermatology and discipline construction in Shenzhen, the Bay Area, and even the whole country.

This forum not only focuses on the clinical diagnosis and treatment needs in the field of dermatology but also aims to promote the system level of production, education, research, and application, and to create a highland for the development of dermatology. The forum attracted the enthusiastic participation of dozens of dermatology experts from Beijing, Guangzhou, Dalian, Changsha, Nanchang, and Shenzhen. Among them, the Hong Kong University Shenzhen Hospital, the Second People's Hospital of Shenzhen, the Southern China Hospital affiliated with Shenzhen University, and the Union Hospital of Huazhong University of Science and Technology in Shenzhen, as members of the Shenzhen Alliance of Rare and Difficult Skin Diseases, attended this academic discussion.

Integrating Chinese and Western medicine, a comprehensive approach to building a fusion ecosystem

This conference attaches importance to the organic integration of traditional medicine and skin health. Tai Tai Pharmaceutical, as a co-organizer of the conference, specially invited Professor Lian Cuihong from the Department of Dermatology of the Second People's Hospital of Shenzhen, Professor Qian Fang from the Department of Dermatology of Shenzhen Hospital of Traditional Chinese Medicine, and Professor Gong Liping from the Department of Dermatology of the Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine to hold a special session on the theme of "Integrated Diagnosis and Treatment of Chloasma with Chinese and Western Medicine," where they conducted in-depth discussions on treatment plans for chloasma.

Chloasma mostly occurs in Asian women of childbearing age, with an overall incidence rate of 8.8%-40%, and is prone to recurrence and difficult to cure. Various treatment methods are available, including chemical peeling, photoelectric therapy, and the use of Taohong Siwu Decoction, etc. of Traditional Chinese medicine internal regulation treatment. In recent years, traditional Chinese medicine internal regulation has achieved good therapeutic effects in the treatment of chloasma.

In the special session on "Tai Tai's Integrated Diagnosis and Treatment of Chloasma with Chinese and Western Medicine," experts discussed and shared the latest research results on the diagnosis and treatment of chloasma from different perspectives. Professor Lian Cuihong shared and summarized multiple research reports, and the results showed that the combined treatment of Chinese and Western medicine for chloasma is more effective. In Professor Gong Liping's view, Taohong Siwu Decoction can activate blood circulation, improve blood microcirculation, and its use with additions and subtractions is more effective than conventional Western medicine treatment for chloasma. Professor Qian Fang pointed out that Taohong Siwu Decoction can inhibit tyrosinase activity, reduce melanin production, and enhance the body's antioxidant capacity. Combining Western medicine with traditional Chinese medicine internal regulation to treat chloasma can achieve better therapeutic effects.

Inheritance Millennium Classic of Traditional Chinese Medicine   Focusing on Chloasma for 30 years

Taohong Siwu Decoction has been passed down for thousands of years, selected into the first batch of "Catalog of Ancient Classic Prescriptions" formulated and issued by the State Administration of Traditional Chinese Medicine, and included in the "Chinese Expert Consensus on the Diagnosis and Treatment of Chloasma (2021 Edition)". Tai Tai Pharmaceutical improved the classic ancient prescription "Taohong Siwu Decoction", using modern high-tech extraction technology to update a pure Chinese herbal preparation, "Tai Tai Red Flower Peach Kernel Oral Liquid", which is more suitable for the physique of Chinese women. Its formula has been granted an invention patent in China. Tai Tai Pharmaceutical pays attention to the real effectiveness of clinical data and conducted a clinical study on this Tai Tai oral liquid, including 98 subjects, a 24-week controlled, double-blind trial to observe the safety, tolerability, and effects on hormone levels and menstrual cycles of Tai Tai oral liquid. The results showed that Tai Tai oral liquid effectively reduced pigmentation caused by chloasma.

Since its launch in 1993, Tai Tai Pharmaceutical has focused on the research of internal regulation and beauty for chloasma for 30 years, always taking the protection, inheritance, and development of the traditional Chinese medicine industry as its responsibility, and actively promoting the essence of traditional Chinese medicine and contributing to cultural revival. As a local pharmaceutical company that has grown and developed together with the Guangdong-Hong Kong-Macao Greater Bay Area, Tai Tai Pharmaceutical will follow the "Action Plan for Greater Health Industry Cluster" under the background of the "Healthy China 2030" planning outline, actively perceive new needs, give full play to the synergistic advantages of research and production, promote the transformation and application of important research results, and help Chinese people create a healthy and naturally beautiful oriental complexion!

Source: China.com.cn